Abstract

Angiopoietins and TIE2 are necessary for blood and lymphatic vessel remodeling during embryonic, postnatal development and homeostasis of the mature vasculature and expected to be a valuable marker in acute leukemia. The present study aimed to assess the expression of TIE2 and angiopoietin-2 in acute leukemia and its correlation with disease behaviour. The study included 62 patients and 19 sex- and age-matched healthy controls, divided into 2 groups, 21 Acute Lymphoblastic Leukaemia (ALL) patients, and 41 Acute Myeloid Leukaemia (AML) patients and 19 sex- and age-matched healthy controls. Bone marrow (BM) aspirate examination, Immunophenotyping and assessment of TIE2 expression for peripheral or BM samples by Flow cytometer and serum angiopoietin-2 by using enzyme-linked immunosorbent assay. The study results showed that TIE2 & Angiopoietin2 were expressed in AML patients more than ALL patients. In ALL patients CD45 and CD5 showed statistically significant correlation with TIE2 but CD45, CD14 showed statistical significance correlation with Angiopoietin2 in AML patients. CD33 was correlated with TIE2 and Angiopoietin2 in AML patients. ROC curve for TIE2 in ALL Cut off >3.8 AUC 0.977 with Sensitivity 90.5% & Specificity 94.7% P-value941 AUC 0.753 with Sensitivity 71.4% & Specificity 78.9% P-value0.002 While in AML TIE2 Cut off>4.8 AUC 0.997 with Sensitivity 95.1% & Specificity 100% P-value1838 AUC 0.871 with Sensitivity 60.9% & Specificity100% P-value <0.001. Univariate logistic regression Analysis of leukemic patients showed that Angiopoietin2, TIE2, WBCs count, Platelets count were Statistically Significant. The present study concluded that TIE2 and angiopoietin-2 positive expression are independent prognostic factor in adult acute leukemia and its expression could characterize a group of acute leukemic patients with monocytic lineage.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.